<DOC>
	<DOCNO>NCT00363259</DOCNO>
	<brief_summary>The purpose study compare sustain virological response rate 24 week end experimental treatment ( induction 72 week ) standard 48 week treatment PEG-inteferon alfa-2b ribavirin patient chronic hepatitis C previous unresponsive interferon alfa monotherapy interferon alfa/ribavirin combination therapy .</brief_summary>
	<brief_title>Pegintron Induction Therapy HCV Non-Responders</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>chronic hepatitis C nonresponse relapse previous interferon therapy without ribavirin least 3 month previous time detectable serum HCVRNA elevate serum ALT activity document least two occasion within past 12 month , least one 90 day screen period precede initiation test drug dose liver biopsy finding ( screen within previous 12 month ) consistent active fibrosis ( haemophiliac exclude biopsy ) compensate liver disease ( ChildPugh Grade A clinical classification ) negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug fertile male females receive ribavirin fertile potentially fertile partner must advise use two form effective contraception ( combine ) treatment 6 month end treatment history evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study woman ongoing pregnancy breast feed therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; 3 month prior first dose study drug investigational drug &lt; 6 week prior first dose study drug positive test screening HBsAg , antiHIV Ab history evidence bleed esophageal varix , ascites , condition consistent decompensated liver disease ( ChildPugh Grade B C clinical classification ) Signs symptom hepatocellular carcinoma history strong evidence medical condition associate chronic liver disease HCV ( e.g. , primary hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure Hb &lt; 7.5 mmol/l woman &lt; 8.6 mmol/l men screen patient increase baseline risk anaemia ( e.g . thalassemia , spherocytosis , etc ) anaemia would medically problematic neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 80,000 cells/mm3 screen serum creatinine level &gt; 1.5 time upper limit normal screen history severe psychiatric disease , especially depression history severe seizure disorder current anticonvulsant use history immunologically mediate disease history evidence chronic pulmonary disease associate functional limitation history severe allergy history symptomatic and/or significant cardiovascular disease poorly control diabetes mellitus history major organ transplantation exist functional graft hyper hypothyroidism evidence severe retinopathy evidence drug abuse ( include excessive alcohol consumption within one year study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>